These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Paiva B; Azpilikueta A; Puig N; Ocio EM; Sharma R; Oyajobi BO; Labiano S; San-Segundo L; Rodriguez A; Aires-Mejia I; Rodriguez I; Escalante F; de Coca AG; Barez A; San Miguel JF; Melero I Leukemia; 2015 Oct; 29(10):2110-3. PubMed ID: 25778100 [No Abstract] [Full Text] [Related]
85. [(89)Zr]oxinate4 for long-term in vivo cell tracking by positron emission tomography. Charoenphun P; Meszaros LK; Chuamsaamarkkee K; Sharif-Paghaleh E; Ballinger JR; Ferris TJ; Went MJ; Mullen GE; Blower PJ Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):278-87. PubMed ID: 25359636 [TBL] [Abstract][Full Text] [Related]
86. Diet-induced obesity promotes a myeloma-like condition in vivo. Lwin ST; Olechnowicz SW; Fowler JA; Edwards CM Leukemia; 2015 Feb; 29(2):507-10. PubMed ID: 25287992 [No Abstract] [Full Text] [Related]
87. SAMSN1 is a tumor suppressor gene in multiple myeloma. Noll JE; Hewett DR; Williams SA; Vandyke K; Kok C; To LB; Zannettino AC Neoplasia; 2014 Jul; 16(7):572-85. PubMed ID: 25117979 [TBL] [Abstract][Full Text] [Related]
88. Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies. Shen K; Xu G; Wu Q; Zhou D; Li J PLoS One; 2014; 9(3):e91461. PubMed ID: 24626254 [TBL] [Abstract][Full Text] [Related]
89. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. Bailey K; Kirk A; Naik S; Nace R; Steele MB; Suksanpaisan L; Li X; Federspiel MJ; Peng KW; Kirk D; Russell SJ PLoS One; 2013; 8(9):e73759. PubMed ID: 24040057 [TBL] [Abstract][Full Text] [Related]
90. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020 [TBL] [Abstract][Full Text] [Related]
91. Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. Otjacques E; Binsfeld M; Rocks N; Blacher S; Vanderkerken K; Noel A; Beguin Y; Cataldo D; Caers J PLoS One; 2013; 8(5):e62818. PubMed ID: 23667526 [TBL] [Abstract][Full Text] [Related]
92. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Xu W; Jones M; Liu B; Zhu X; Johnson CB; Edwards AC; Kong L; Jeng EK; Han K; Marcus WD; Rubinstein MP; Rhode PR; Wong HC Cancer Res; 2013 May; 73(10):3075-86. PubMed ID: 23644531 [TBL] [Abstract][Full Text] [Related]
93. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. Kearl TJ; Jing W; Gershan JA; Johnson BD J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570 [TBL] [Abstract][Full Text] [Related]
94. Age matters: Young T lymphocytes offer better protection from myeloma proliferation. Glick AF; Song YS; Hwang B; Lillvis J; Zanzonico P; Fuchs C; Pearse RN; Szabo P; Weksler ME Immun Ageing; 2013 Feb; 10(1):5. PubMed ID: 23419047 [TBL] [Abstract][Full Text] [Related]
95. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. Tesfay MZ; Kirk AC; Hadac EM; Griesmann GE; Federspiel MJ; Barber GN; Henry SM; Peng KW; Russell SJ J Virol; 2013 Apr; 87(7):3752-9. PubMed ID: 23325695 [TBL] [Abstract][Full Text] [Related]
96. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. Hofgaard PO; Jodal HC; Bommert K; Huard B; Caers J; Carlsen H; Schwarzer R; Schünemann N; Jundt F; Lindeberg MM; Bogen B PLoS One; 2012; 7(12):e51892. PubMed ID: 23284805 [TBL] [Abstract][Full Text] [Related]
97. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Hu J; Van Valckenborgh E; Menu E; De Bruyne E; Vanderkerken K Dis Model Mech; 2012 Nov; 5(6):763-71. PubMed ID: 23115205 [TBL] [Abstract][Full Text] [Related]
98. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578 [TBL] [Abstract][Full Text] [Related]
99. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Fowler JA; Mundy GR; Lwin ST; Edwards CM Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979 [TBL] [Abstract][Full Text] [Related]
100. Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Sharabi A; Haran-Ghera N Bone Marrow Res; 2011; 2011():269519. PubMed ID: 22046558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]